Proteinase Patents (Class 435/219)
-
Publication number: 20140193831Abstract: The present invention relates to a method of predicting a plant seed trait, such as germination rate, vigour, aging and priming, by determining the presence of a target protein, i.e. diagnostic marker, in its active state in a protein sample derived from a plant seed or plant seed lot. Thereby, the quality of a plant seed or a plant seed lot can be predicted and/or diagnosed and seeds may be distinguished on basis of their characteristics and with respect to the traits described herein. Inter alia, seeds and seed lots having high germination quality may be distinguished from seeds and seed lots having low germination quality.Type: ApplicationFiled: January 30, 2012Publication date: July 10, 2014Applicants: GAUTIER SEMENCES, NINSAR AGROSCIENCES SLInventors: Renier A. L. Van Der Hoorn, Christian Gu, Kaschani Farnusch, Johana Misas, Kerstin Richau, Izabella Kolodziejek, Oscar Goni Ramos, Xavier Berthet, Philippe Ellul, Frédéric Moquet, Capucine Malliart
-
Patent number: 8771994Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: February 12, 2013Date of Patent: July 8, 2014Assignee: Novozymes Inc.Inventor: Nikolaj Spodsberg
-
Patent number: 8771993Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: February 12, 2013Date of Patent: July 8, 2014Assignees: Novozymes A/S, Novozymes Inc.Inventor: Nikolaj Spodsberg
-
Publication number: 20140186923Abstract: Disclosed herein are compounds, compositions, methods and kits for purifying a serine protease and serine proteases purified with the compounds, compositions and methods.Type: ApplicationFiled: March 14, 2013Publication date: July 3, 2014Applicant: Portola Pharmaceuticals, Inc.Inventor: Portola Pharmaceuticals, Inc.
-
Patent number: 8765441Abstract: The invention provides novel biologically pure cultures of microorganisms high in protease activity and capable of decomposing proteins recalcitrant to proteolysis as contained in garbage, waste water, organic waste liquids, industrial wastes and the like, a protease produced by such microorganisms and capable of decomposing proteins recalcitrant to proteolysis, and a method of utilizing the same. The novel culture is of a soil-derived microorganism belonging to Streptomyces sp., or a strain derived therefrom, which produces a protease capable of efficiently decomposing proteins recalcitrant to proteolysis as contained in waste water, organic waste liquids, industrial wastes and so forth.Type: GrantFiled: August 9, 2011Date of Patent: July 1, 2014Assignee: Microbial Chemistry Research FoundationInventors: Hiroyasu Doi, Naoko Kinoshita, Tatsuzo Oka, Zhao Hui
-
Patent number: 8765471Abstract: The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production is mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.Type: GrantFiled: April 15, 2013Date of Patent: July 1, 2014Assignee: Nordmark Arzneimittel GmbH & Co. KGInventors: Manfred Kurfuerst, Christian Raemsch, Nicole Raemsch-Guenther, Olaf Friedrich, Silke Huettler, Daniel Brandhorst, Thierry Berney, Pascal Bucher, Heide Brandhorst
-
Patent number: 8759067Abstract: The present invention relates to potato virus NIa protease variants or fragments thereof, polynucleotides encoding them, and methods of making and using the foregoing.Type: GrantFiled: March 22, 2013Date of Patent: June 24, 2014Assignee: Centocor Ortho Biotech Inc.Inventors: Ellen Chi, Michael Hunter, Ronald Swanson
-
Patent number: 8759026Abstract: The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.Type: GrantFiled: September 19, 2012Date of Patent: June 24, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Leopold Grillberger, Alexandra Spenger, Meinhard Hasslacher, Rana Grillberger, Manfred Reiter
-
Patent number: 8759040Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: February 12, 2013Date of Patent: June 24, 2014Assignee: Novozymes Inc.Inventor: Nikolaj Spodsberg
-
Patent number: 8759041Abstract: The present invention relates to isolated polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: February 12, 2013Date of Patent: June 24, 2014Assignee: Novozymes Inc.Inventor: Nikolaj Spodsberg
-
Publication number: 20140170701Abstract: Disclosed is a method for producing a recombinant protein of interest which is characterised by the following steps: (a) providing a first part of an Npro autoprotease and providing a second part of an Npro autoprotease, wherein said second part is fused by a peptidic bond to a protein of interest but said second part alone does not exhibit a proteolytic activity, and wherein complementation of said first part with the second part forms an autoproteolytically active Npro autoprotease, (b) contacting the first part of the Npro autoprotease with the second part of the Npro autoprotease so that an autoproteolytically active Npro autoprotease is formed and the protein of interest fused by the peptidic bond to the second part of the Npro autoprotease is proteolytically cleaved off the second part of the Npro autoprotease at the peptidic bond, and (c) recovering the protein of interest.Type: ApplicationFiled: December 19, 2013Publication date: June 19, 2014Applicants: Boehringer Ingelheim RCV GmbH & Co KG, Sandoz AGInventors: Michael SPONRING, Rainer SCHNEIDER, Bernhard AUER
-
Publication number: 20140170702Abstract: Disclosed is a method for producing a recombinant protein of interest, the method being characterised in by the following steps: (a) providing a fusion protein comprising an Npro autoprotease moiety and a protein of interest moiety in inclusion bodies, (b) solubilising the inclusion bodies, (c) allowing the fusion protein to be cleaved by the Npro autoprotease moiety under chaotropic conditions, wherein the recombinant protein of interest is cleaved from the fusion protein and wherein the recombinant protein of interest is not yet renatured or simultaneously renatured, and (d) recovering the protein of interest, optionally including a renaturing step for the protein of interest.Type: ApplicationFiled: December 19, 2013Publication date: June 19, 2014Applicants: Boehringer Ingelheim RCV GmbH & Co KG, Sandoz AGInventors: Maria REITMEIR, Rainer SCHNEIDER, Bernhard AUER
-
Patent number: 8753860Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: February 12, 2013Date of Patent: June 17, 2014Assignee: Novozymes A/SInventors: Marc D. Morant, Paul Harris
-
Patent number: 8742336Abstract: There are provided a bio-chip for secondary ion mass spectrometry and a method of fabricating the same, the bio-chip, which is a bio-chip for analyzing a biochemical material using the secondary ion mass spectrometry, including: a substrate; and core-shell particles positioned above substrate, wherein the core-shell particles each include a metal nanoparticle as a core and a metal shell surrounding the metal nanoparticle.Type: GrantFiled: December 26, 2012Date of Patent: June 3, 2014Assignee: Korea Research Institute of Standards and ScienceInventors: Young-Pil Kim, Tae Geol Lee
-
Patent number: 8741286Abstract: The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders.Type: GrantFiled: June 4, 2013Date of Patent: June 3, 2014Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Olivier Christophe, Cecile Denis, Ghislaine Cherel, Paul Gueguen
-
Publication number: 20140147429Abstract: The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor.Type: ApplicationFiled: May 16, 2012Publication date: May 29, 2014Applicant: SYNTAXIN LIMITEDInventors: John Chaddock, Elaine Harper
-
Publication number: 20140141473Abstract: Yeast cell belonging to the genus Saccharomyces having introduced into its genome at least one xylA gene and at least one of each of araA, araB and araD genes and that is capable of consuming a mixed sugar mixture comprising glucose, xylose and arabinose, wherein the cell co-consumes glucose and arabinose, has genetic variations obtained during adaptive evolution and has a specific xylose consumption rate in the presence of glucose that is 0.25 g xylose/h, g DM or more.Type: ApplicationFiled: April 20, 2012Publication date: May 22, 2014Applicant: DSM IP ASSETS B.V.Inventors: Paul Klaassen, Bianca Elisabeth Maria Gielesen, Gijsberdina Pieternella Van Suylekom, Panagiotis Sarantinopoulos, Wilbert Herman Marie Heijne, Aldo Greeve
-
Publication number: 20140140980Abstract: Provided herein are compositions, foods comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof for modulating gluten intolerance and related conditions, such as celiac disease.Type: ApplicationFiled: June 6, 2013Publication date: May 22, 2014Inventor: David Schriemer
-
Publication number: 20140127782Abstract: The present invention relates to novel JP170 like subtilases from wild-type bacteria, hybrids thereof and to methods of construction and production of these proteases. Further, the present invention relates to use of the claimed subtilases in detergents, such as a laundry or an automatic dishwashing detergent.Type: ApplicationFiled: January 8, 2014Publication date: May 8, 2014Applicant: Novozymes A/SInventors: Preben Nielsen, Poul Erik Pedersen, Helle Outtrup
-
Publication number: 20140128287Abstract: A system allows for rapid and specific induction of individual genes in eukaryotic cells using a chimeric transcriptional activator that is responsive to hormone inducer. Upon addition of the hormone, cytoplasmic transcriptional activator localizes to the nucleus and subsequently binds to promoters containing sequences that bind to its DNA-binding domain. Genetic modifications allow for rapid and specific degradation of a targeted protein upon addition of hormone by means of a regulated degron method that utilizes a protease variant. This system is useful for discovering new compounds by high throughput screening when introducing compound libraries to these protein-depleted cells.Type: ApplicationFiled: June 15, 2012Publication date: May 8, 2014Applicant: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Sanford Jay Silverman, Robert Scott McIsaac, Marcus Noyes, David Botstein
-
Patent number: 8697414Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.Type: GrantFiled: August 16, 2013Date of Patent: April 15, 2014Assignee: Allergan, Inc.Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
-
Patent number: 8697413Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.Type: GrantFiled: August 16, 2013Date of Patent: April 15, 2014Assignee: Allergan, Inc.Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
-
Patent number: 8691519Abstract: The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.Type: GrantFiled: March 19, 2013Date of Patent: April 8, 2014Assignee: The J. David Gladstone InstitutesInventors: Li Gan, Lennart Mucke
-
Publication number: 20140093491Abstract: The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Gal?1,3G al glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII.Type: ApplicationFiled: May 2, 2013Publication date: April 3, 2014Applicant: LFB BIOTECHNOLOGIESInventor: LFB BIOTECHNOLOGIES
-
Patent number: 8685693Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.Type: GrantFiled: March 18, 2013Date of Patent: April 1, 2014Assignee: Allergan, Inc.Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
-
Patent number: 8685692Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.Type: GrantFiled: March 18, 2013Date of Patent: April 1, 2014Assignee: Allergan, Inc.Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
-
Publication number: 20140080200Abstract: The present invention relates to improved processes for purifying polypeptides of interest by increasing the amount of a polypeptide of interest bound to an ion-exchange matrix relative to the amount of one or more impurities bound to the ion-exchange matrix. This effect is achieved by adding a chemical compound in the process which by also binding to the ion-exchange matrix due to a change that is opposite to the change of the ion-exchange matrix, reduces the binding of impurities more than the binding of the polypeptide of interest.Type: ApplicationFiled: December 15, 2010Publication date: March 20, 2014Applicant: CSL LIMITEDInventors: Adam Charlton, Mark Napoli, Paul Smrdelj, Anthony Stowers, Vicky Pirzas, Magnus Schröder, Ian Walker
-
Publication number: 20140079671Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: ApplicationFiled: September 19, 2011Publication date: March 20, 2014Applicants: TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA, TECNIFAR-INDÚSTRIA TÉCNICA FARMACÊUTICA, S.A.Inventors: Miguel Ângelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel Martins Barbosa
-
Publication number: 20140050718Abstract: A method for treating a patient suffering from a condition with an active compound comprising the steps of (a) treating the patient intranasally with an effective amount of MMP-9 or a functionally equivalent fragment, wherein the tight junctions of the patient's nasal epithelial cells are modulated or wherein the basal lamina of the patient is partially digested and type IV collagen of the patient is degraded or wherein access to the patient's perineural, perivascular, or lymphatic compartment spaces is facilitated and (b) treating the patient intranasally with an active compound is disclosed.Type: ApplicationFiled: August 14, 2013Publication date: February 20, 2014Applicant: Wisconsin Alumni Research FoundationInventors: Robert Gary Thorne, Jeffrey James Lochhead
-
Publication number: 20140030791Abstract: MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis.Type: ApplicationFiled: May 20, 2013Publication date: January 30, 2014Inventors: Sandra Waugh Ruggles, Jack Nguyen
-
Publication number: 20140017764Abstract: Provided are methods for protein engineering, such as engineering proteases or kinases. The methods may utilize yeast display and/or ER sequestration of proteins or substrates. In some aspects, TEV proteases with altered substrate specificity, potency, and/or efficiency are provided.Type: ApplicationFiled: June 25, 2013Publication date: January 16, 2014Applicant: Research Development FoundationInventors: Brent L. IVERSON, George GEORGIOU, Joseph M. TAFT, Li YI
-
Patent number: 8623810Abstract: We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds.Type: GrantFiled: March 3, 2010Date of Patent: January 7, 2014Assignee: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Frank Niehaus, Jürgen Eck, Renate Schulze, Michael Krohn
-
Publication number: 20130337503Abstract: The present invention provides a mutant 27 kDa NIa proteinase having reduced self-cleavage activity relative to the self-cleavage activity of its wild-type proteinase. The mutant has the same substrate cleavage activity as the wild-type proteinase but is more stable than the wild-type proteinase. The present invention also provides a method of obtaining large quantities of active 27 kDa NIa proteinase for use as a tool for purification of other proteins.Type: ApplicationFiled: May 21, 2013Publication date: December 19, 2013Applicant: YALE UNIVERSITYInventors: Jennifer A. DOUDNA, Louise J. Lucast, Robert T. Batey
-
Patent number: 8609389Abstract: The present invention provides an improved type protease which comprises an amino acid sequence that is at least 75% identical to SEQ ID NO:3, said improved type protease has at least one mutation selected from the group consisting of: (A) replacement of glutamine corresponding to glutamine at position 265 in SEQ ID NO: 3 with an acidic amino acid; and (B) replacement of glutamine at position 266 in SEQ ID NO: 3 with an acidic amino acid, and wherein said improved type protease has milk-clotting activity.Type: GrantFiled: March 19, 2010Date of Patent: December 17, 2013Assignee: Meito Sangyo Co., Ltd.Inventors: Kazunori Harada, Hiroyuki Kobayashi, Taro Suga, Hiroyuki Yamaguchi, Akira Tsunoda, Shigeaki Kato
-
Publication number: 20130330758Abstract: At least at least one embodiment of the present invention relates to a method for using a high pressure-resistant enzyme in a high pressure condition; a method for promoting the activity of the high pressure-resistant enzyme by means of a high pressure treatment; a composition, which contains the high pressure-resistant enzyme, for decomposing proteins under a high pressure condition; a composition, which contains the composition for decomposing proteins, for preparing natural flavoring substances; a container for high pressure treatment, which contains the composition for decomposing proteins; and a method for measuring the activity of the high pressure-resistant enzyme, which comprises a step of decomposing an azocasein solution serving as a substrate by using the high pressure-resistant enzyme treated under a high pressure condition.Type: ApplicationFiled: February 20, 2012Publication date: December 12, 2013Applicant: KOREA FOOD RESEARCH INSTITUTEInventors: Nam-Soo Kim, Chong-Tai Kim, Yong-Jin Cho, Chul-Jin Kim, Jin-Soo Maeng, Soo-Jin Kwon
-
Patent number: 8603437Abstract: The present invention discloses a method for the enzyme-mediated, site-specific, in-vivo precipitation of a water soluble molecule in an animal. The enzyme is either unique to tumor cells, or is produced within a specific site (e.g., tumor) at concentrations that are higher than that in normal tissues. Alternatively, the enzyme is conjugated to a targeting moiety such as an antibody or a receptor-binding molecule.Type: GrantFiled: April 30, 2012Date of Patent: December 10, 2013Assignee: President and Fellows of Harvard CollegeInventors: Amin I. Kassis, Ravi S. Harapanhalli
-
Publication number: 20130315915Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: April 30, 2013Publication date: November 28, 2013Applicant: Celera CorporationInventors: Steve RUBEN, Tao HE, Candy LEE, Karen VAN ORDEN, Paul MOORE
-
Publication number: 20130316455Abstract: Solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer. Processes of preparing the solutions and suspensions are also disclosed. The solutions and suspensions may be employed in methods of isolating mammalian cells, such as pancreatic islets, methods of preserving mammalian tissue and organs, methods of aiding the recovery of mammalian cells following their isolation, methods of maintaining mammalian cells, methods of propagating mammalian cells, and methods of treating a mammal with diabetes.Type: ApplicationFiled: January 31, 2013Publication date: November 28, 2013Applicants: The Board of Trustees of the University of IIlinois, OPK Biotech, LLC.Inventors: OPK Biotech, LLC., The Board of Trustees of the University of IIlinois
-
Patent number: 8592200Abstract: The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample.Type: GrantFiled: December 21, 2012Date of Patent: November 26, 2013Assignee: University of South FloridaInventor: Matt Ewert
-
Publication number: 20130309753Abstract: A recombinant serine protease precursor that auto-activates in an aqueous buffer to form a mature active enzyme is disclosed. A contemplated precursor contains 1 to about 10 heterologous amino acid residues that function to enhance by at least ten-fold the room temperature rate of auto-lytic bond cleavage to form the active enzyme relative to the auto-lytic cleavage rate of the native enzyme precursor when each precursor is dispersed in an aqueous buffer at an optimal pH value for the proteolytic activity of the protease. Illustrative active enzymes include serine proteases such as thrombin and protein C. A method of preparing and using an enzyme precursor is also disclosed.Type: ApplicationFiled: May 16, 2012Publication date: November 21, 2013Applicant: SAINT LOUIS UNIVERSITYInventors: Nicola Pozzi, Enrico Di Cera, Sergio Barranco-Medina
-
Patent number: 8586325Abstract: Enzyme substrates and associated technology of the present invention are provided. An enzyme substrate of the invention may comprise a biologically functional fluorescent dye and an enzyme-specific substrate moiety attached in such a way that the functionality of the functional dye is diminished. An enzymatic reaction may cleave at least a portion of the substrate moiety from the enzyme substrate to provide a more functional product dye. This product dye may be nonfluorescent or weakly fluorescent, in general, and relatively fluorescent, in a particular condition, such as when bound to a partner biological molecule or an assembly of partner biological molecules. An enzyme substrate of the present invention may thus be useful in fluorescence detection, and/or in any of a variety of useful applications, such as the detection of enzymatic activity in a cell-free system or in a living cell, the screening of drugs, or the diagnosis of disease.Type: GrantFiled: May 10, 2013Date of Patent: November 19, 2013Assignee: Biotium, Inc.Inventors: Fei Mao, Hui Cen
-
Publication number: 20130302839Abstract: The present invention relates to a method for detecting at least one direct factor Xa inhibitor in a sample other than citrate plasma, comprising the step of mixing a sample containing a factor Xa inhibitor with a composition containing factor Xa under conditions which allow the factor Xa to release a detectable substance from a chromogenic substrate.Type: ApplicationFiled: November 7, 2011Publication date: November 14, 2013Applicant: UNIVERSITAT HEIDELBERGInventors: Job Harenberg, Roland Krämer
-
Patent number: 8580557Abstract: The present invention relates to a casein hydrolysate containing free amino acids and in vivo indigestible peptides having minimally suppressed in vivo enzymatic digestibility, and expected to express functions, such as hypotensive effect, in living organism, and to a method for preparing such a hydrolysate, and use thereof. The casein hydrolysate of the present invention contains free amino acids and peptides, such as in vivo indigestible peptides including Xaa-Pro and Xaa-Pro-Pro, obtained by hydrolyzing animal milk casein to have an average chain length of not longer than 2.1 in terms of the number of amino acid residues, and has ACE inhibitory activity or hypotensive effect.Type: GrantFiled: September 1, 2010Date of Patent: November 12, 2013Assignee: Calpis Co., Ltd.Inventors: Naoyuki Yamamoto, Seiichi Mizuno, Takanobu Gotou, Keiichi Matsuura, Tadashi Shinoda, Hideo Nishimura
-
Publication number: 20130295646Abstract: The invention relates to a method for extracting a protein from milk, having at least one hydrophobic pocket and a negative charge to the natural pH of milk, that comprises the following steps: a) skimming and delipidation of the milk; b) passing the delipidated and skimmed fraction containing the protein on a chromatographic substrate on which is grafted a ligand having both a hydrophobic characteristic and an ionic characteristic in pH conditions enabling the protein to be retained on the substrate, the pH being higher than 4.6; c) elution of the protein; d) purification of the eluted fraction by removing the milk proteins from the eluted fraction; and e) recovering the protein.Type: ApplicationFiled: June 5, 2013Publication date: November 7, 2013Applicant: LFB BIOTECHNOLOGIESInventors: Alain LEJARS, Michel Nogre, Monique Ollivier
-
Patent number: 8574884Abstract: The present invention provides methods and compositions comprising at least one neutral metalloprotease enzyme that has improved storage stability. In some embodiments, the neutral metalloprotease finds use in cleaning and other applications. In some particularly preferred embodiments, the present invention provides methods and compositions comprising neutral metalloprotease(s) obtained from Bacillus sp. In some more particularly preferred embodiments, the neutral metalloprotease is obtained from B. amyloliquefaciens. In still further preferred embodiments, the neutral metalloprotease is a variant of the B. amyloliquefaciens neutral metalloprotease. In yet additional embodiments, the neutral metalloprotease is a homolog of the B. amyloliquefaciens neutral metalloprotease. The present invention finds particular use in applications including, but not limited to cleaning, bleaching and disinfecting.Type: GrantFiled: January 6, 2012Date of Patent: November 5, 2013Assignee: Danisco US Inc.Inventors: Andrew Shaw, Louise Wallace, David A. Estell, Ronaldus W. J. Hommes, Sang-Kyu Lee, Hiroshi Oh, Eugene S. Sadlowski
-
Publication number: 20130287759Abstract: Compositions comprising collagenase G and collagenase H (in a ratio between 1:2.5 and 1:3.5), optionally formulated in hydrogels, and its uses as medicament for the treatment of diseases involving alterations of collagen, such as fibromatosis, palmar Dupuytren's contracture, La Peyronie's disease, Ledderhose's disease or retractable scars.Type: ApplicationFiled: September 30, 2011Publication date: October 31, 2013Applicant: PROTEOS BIOTECH S.L.U.Inventor: Juan Ramón Muñoz Montano
-
Publication number: 20130280787Abstract: The present invention relates to a method for extracting nucleic acids from a wax-embedded sample, the use of particular solvents for removing wax from a wax-embedded sample in a method for extracting, isolating and/or purifying nucleic acids from a crosslinked wax-embedded sample as well as to a kit for extracting, isolating and/or purifying nucleic acids from a wax-embedded sample.Type: ApplicationFiled: June 14, 2011Publication date: October 24, 2013Applicant: QIAGEN GmbHInventors: Markus Mueller, Thorsten Singer, Esther Rosenberg, Joerg Hucklenbroich
-
Publication number: 20130273027Abstract: Mutant enzymes and methods of use thereof are provided.Type: ApplicationFiled: March 13, 2013Publication date: October 17, 2013Inventors: Craig Leach, Michael Eddins, David Stemer, Benjamin Nicholson
-
Publication number: 20130273590Abstract: The present invention relates to methods, systems, and kits for intoxicating cells, neuronal and non-neuronal cells, with a toxin or fragment thereof. This is done by subjecting toxin substrate and a lipid or polymeric carrier (e.g., DNA uptake facilitating agent) to one or more cells for use in cell based assays. In an aspect, the methods of the present invention allow for high throughput assays and, as such, for the evaluation of drug candidates.Type: ApplicationFiled: June 25, 2013Publication date: October 17, 2013Inventors: George A. Oyler, Charles B. Shoemaker, Chuehling Kuo
-
Publication number: 20130273601Abstract: The present invention relates to a yeast cell comprising one or more exogenous genes of a pentose metabolic pathway non-native to the yeast cell wherein the yeast cell has a disruption of the hxk1, hxk2 glk1 and gal1 native in the yeast cell. The invention further relates to pentose and glucose fermenting yeast cell that is capable of simultaneous pentose and glucose consumption.Type: ApplicationFiled: October 11, 2011Publication date: October 17, 2013Applicant: DSM IP ASSETS B.V.Inventors: Hendrik Wouter Wisselink, Antonius Jeroen Adriaan Van Maris, Jacobus Thomas Pronk